Giant orf with prolonged recovery in a patient with psoriatic arthritis treated with etanercept.
نویسندگان
چکیده
Orf, also known as contagious ecthyma or contagious pustular dermatitis, is a viral skin infection caused by a parapoxvirus (1). It typically manifests as a nodule of the hands that heals spontaneously within 3–6 weeks, but other sites such as the head and scalp, are occasionally involved. Orf is common among persons with regular contact with sheep and goats, including farmers, butchers and veterinary surgeons (1). In immunocompromised patients the infection many cause lesions with excessive growth and be long-lasting and difficult to treat. Several cases of orf have been reported in patients using im-munosuppressive medications, such as glucocorticoids, cyclosporine, mycophenolate and tacrolimus, after transplantations (2–5), but to our knowledge this is the first report of giant orf in a patient treated with a tumour necrosis factor (TNF) inhibitor. The patient was a 45-year-old man treated for psoria-tic arthritis with etanercept (Enbrel) 50 mg per week for 2 years. He had been a sheep farmer for 28 years, but had never been infected with orf before, although he had observed crusts in the oral area of his lambs, which were probably orf infections, for many seasons previously. The lambs were out at grass all summer, and in the autumn they should be given an oral anti-parasitic solution. In relation to this episode he observed that a few of the lambs had crusts around the mouth. While handling the lambs his face was exposed to saliva from 2 different lambs. On that occasion, he already had an abrasion in the temporal area from an unrelated activity. After this episode the patient developed a rapidly growing tumour in the right temporal area over a period of 3 months and at the same time a more slowly growing tumour on a finger. Clinical examination showed an exo phytic, lobulated and raspberry-like structure rising 5–6 cm above the temporal surface, with the largest transverse diameter of 7 cm (Fig. 1). He also had a typical, but far smaller, lesion on the third finger of the left hand. Histological examination confirmed the clinical diagnosis. As only a few cases of giant orf have been reported in immunosuppressed patients, management of this patient category has not been clearly established. In single cases , treatment with topical cidofovir (2) or imiquimod (5) has been successful, and the use of cryotherapy (3) and surgical excision (4) has also been described. Due to the large size of the temporal …
منابع مشابه
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
BACKGROUND Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the treatment of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which tumour necrosis factor, a proinflammatory cytokine, is present in increased concentrations in joints and in the skin. Therefore, psoriatic arthritis and psoriasis may be appropriate therapeutic targets for etanercep...
متن کاملFrom ankylosis to pencil-in-cup deformity in psoriatic arthritis: a case report.
A 56-year-old woman with psoriatic arthritis is presented whose initially ankylosed digit was later found to develop pencil-in-cup change. The patient was treated over that period with etanercept and had no signs of active arthritis. The possible mechanisms for these changes are discussed.
متن کاملCosts of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
BACKGROUND Several anti-inflammatory biologic medications are available in the United States for the treatment of moderate-to-severe rheumatoid arthritis, moderate-to-severe psoriasis, psoriatic arthritis, or ankylosing spondylitis. The tumor necrosis factor (TNF) blockers etanercept, adalimumab, and infliximab are approved for use in adults with any of these conditions, but predicting the annu...
متن کاملPatient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
OBJECTIVE To evaluate the effects of etanercept treatment on patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA). METHODS A 24-week double-blind comparison to placebo was followed by a 48-week open-label phase in which all eligible patients received etanercept. PRO were measured using the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), the Medical Ou...
متن کاملComparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study
BACKGROUND The relative cost of biologics in the treatment of autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis, is a key consideration for managed care payers. OBJECTIVES Our objective was to estimate biologic costs and treatment patterns in US managed care patients with rheumatoid arthritis, psoriatic arthritis, psoriasis, and/o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Acta dermato-venereologica
دوره 93 4 شماره
صفحات -
تاریخ انتشار 2013